UNyango lwePrimary Lung Cancer 2026: Izikhokelo ezitsha kunye noNyango lwamva nje 

Unyango lomhlaza wemiphunga olusisiseko ngo-2026 lugxile kunyango oluchanekileyo, ukudibanisa uvavanyo oluphambili lwe-biomarker kunye nonyango olulungiselelweyo lwenkqubo. Njengoyena nobangela uphambili wokubhubha komhlaza kwihlabathi liphela, ulawulo ngoku luxhomekeke kwi-AJCC 9th Edition kunye nezikhokelo ezihlaziyiweyo ze-NCCN. Imigangatho yangoku igxininisa iprofayili yeemolekyuli kubaqhubi abafana ne-EGFR, i-HER2, kunye ne-KRAS ukukhetha ii-arhente ezijoliswe kuzo okanye i-immunotherapies ngaphambi kokuqwalasela i-chemotherapy yendabuko.

Ukuqonda uMhlaza oPhambili weMiphunga kunye neMigangatho yokuHlola ka-2026

Umhlaza wemiphunga wokuqala usuka kwiithishu zemiphunga, ikakhulu ezihlelwa kumhlaza wemiphunga ongeyonxalenye encinci (NSCLC) kunye nomhlaza wemiphunga omncinci weseli (SCLC). I-NSCLC ithatha malunga ne-85% yazo zonke iimeko, kubandakanywa i-adenocarcinoma kunye ne-squamous cell carcinoma subtypes. Ukuxilongwa ngokuchanekileyo sisiseko sempumelelo unyango lomhlaza wemiphunga yokuqala, ukugqiba ukuba ngaba isigulane sifanelekile utyando lokunyanga okanye lufuna ulawulo lwenkqubo.

Ngo-2026, iiprothokholi zokuxilonga ziye zavela kakhulu ngokwamkelwa jikelele kwenkqubo yesiteji ye-AJCC ye-9th Edition TNM. Olu hlaziyo lubonelela ngedatha ye-granular prognostic engaphezulu, evumela oogqirha ukuba bahlule phakathi kwe-microscopic kunye ne-macroscopic yokubandakanyeka kwe-nodal ngokuchaneka okukhulu. Utshintsho luqinisekisa ukuba izigqibo zonyango zihambelana nemigangatho yamazwe ngamazwe, ukwandisa iziphumo zokusinda ngeendlela zokhathalelo lomntu.

Indima ebalulekileyo yoVavanyo lweBiomarker

Uvavanyo olubanzi lwe-biomarker luye lwaba sisinyanzelo phambi kokuba kuqaliswe unyango lwezifo ezihambele phambili. Isigama silungelelaniswe "kuvavanyo lwe-biomarker," ithatha indawo yamagama amadala anje ngemolekyuli okanye ukuhlolwa kofuzo. Izikhokelo zale mihla zicebisa indlela embaxa-mbili kusetyenziswa i-tissue biopsy edityaniswa yi-plasma liquid biopsy ukunyusa amazinga okubhaqwa.

• Abaqhubi abangundoqo: Uvavanyo kufuneka lufake i-EGFR, ALK, ROS1, BRAF, KRAS, MET, RET, NTRK, kunye ne-ERBB2 (HER2).
• Ujoliso oluvelayo: I-NRG1 fusions ngoku ivavanywa rhoqo kusetyenziswa i-RNA-based Next Generation Sequencing (NGS).
• Iimpawu ze-Immunotherapy: Amanqanaba enkcazo ye-PD-L1 ahlala ebaluleke kakhulu ekumiseleni ukufaneleka kwe-checkpoint inhibitors.

Ukuba iziphumo ze-biomarker zisalindile, iiprothokholi zangoku zicebisa ukulibazisa ukuqaliswa kwe-immunotherapy ukuthintela ukuqhubela phambili kwe-hyper-progression okanye ukunciphisa ukusebenza kakuhle kubantu abaqhuba kakuhle. Le ndlela yobulumko igxininisa ukutshintshela ekuqhutyweni kwedatha unyango lomhlaza wemiphunga yokuqala izicwangciso.

IziKhokelo zoNyango eziHlaziyiweyo zoMhlaza ongeNcinane weMiphunga yeSeli

I-landscape yolawulo lwe-NSCLC itshintshile ngokukhululwa kwe-2026 NCCN yeZikhokelo zokuSebenza kwezonyango. Olu hlaziyo lubonisa ukuqonda okunzulu kwebhayoloji yethumba kunye nokufumaneka kweearhente zonyango ezinoveli. Izikhokelo zibeka phambili iindlela zonyango ezijoliswe kuzo kwizigulane ezinokuguqulwa okusebenzayo, ukugcina i-chemotherapy kunye ne-immunotherapy kwiimeko ezithile okanye isifo somqhubi.

Unyango lokuQala loGuquko oluSebenzayo

Kwizigulane ezineenguqu ezithile zofuzo, i-tyrosine kinase inhibitors (TKIs) imele umgangatho wegolide. Uhlaziyo oluphawulekayo ekuqaleni kwe-2026 lubandakanya isincomo se-zonugritinib kunyango lokuqala lwe-NSCLC ye-metastatic kunye ne-ERBB2 (HER2) ukuguqulwa kwesizinda se-tyrosine kinase. Olu vumo lulandela idatha enyanzelisayo evela kuphononongo lwe-Beamion LUNG-1, ebonisa iireyithi zokuphendula ezinenjongo eziphezulu kunye nokusinda okungapheliyo ngaphandle kokuqhubela phambili.

Ngaphambili, umhlaza wemiphunga oguqukayo we-HER2 ubungenazo iindlela ezisebenzayo ekujoliswe kuzo, zihlala zinyanzelisa ukuthembela kwii-antibody-drug conjugates emva kokusilela kwechemotherapy. Ukubandakanywa kwe-TKI enamandla, engaguqukiyo itshintsha i-algorithm yokonyango, inika ukhetho lomlomo olunyamezelwe kakuhle kunye nenzuzo ebalulekileyo yeklinikhi. Oku kubonisa isantya esikhawulezayo sokwenziwa kwezinto ezintsha unyango lomhlaza wemiphunga yokuqala.

Ezinye iithagethi ezisekiweyo ziyaqhubeka nokubona ulungiso. Kwisifo esiguquliweyo se-EGFR, isizukulwana sesithathu se-TKIs sihlala singumqolo, ngelixa iindibaniselwano ezintsha zijolise ukoyisa iindlela zokuxhathisa. Ngokufanayo, i-ALK inhibitors iye yavela ukuze ibonelele ngokungena kwenkqubo ye-nervous central, ukujongana nendawo eqhelekileyo yokubuyela kwakhona.

I-Immunotherapy kunye ne-Chemotherapy Combinations

Ukungabikho kokuguqulwa komqhubi, i-chemo-immunotherapy ihlala ingumgangatho wokunyamekela kwizigulane ezininzi ezine-NSCLC ephezulu. Izikhokelo ze-2026 ziphucula ukhetho lwesigulane ngokusekelwe kwi-PD-L1 inkcazo kunye ne-histological subtypes. Ngokucacileyo, inkcazo "yengozi enkulu" yokuphindaphinda iye yanda ukuze ibandakanye iimpawu ezithile zeemolekyuli nakwisifo sokuqala.

Izicwangciso ze-Neoadjuvant ziye zafumana i-traction, zisebenzisa i-immunotherapy edibeneyo ne-platinum-doublet chemotherapy ngaphambi kokuhlinzwa. Uhlaziyo lwakutsha nje lucacisa uhlengahlengiso lwerejimeni, njengokutshintsha i-paclitaxel nge-docetaxel kwindibaniselwano ethile esekwe kwi-cisplatin ukukhulisa ukunyamezela ngaphandle kokuphazamisa ukusebenza kakuhle. Le ndlela yokusebenza ijolise ekwehliseni amathumba kunye nokuphelisa i-micrometastases kwangoko.

Ukuqhubela phambili kuLawulo loMhlaza weMiphuphu yeSeli encinci

Umhlaza wemiphunga omncinci weseli (SCLC) uhlala unobungozi obunoburhalarhume obubonakaliswa kukukhula okukhawulezayo kunye ne-metastasis yokuqala. Ngelixa ngokwembali yayinyangwa ngerejimeni yechemotherapy efanayo, izikhokelo zowama-2026 zazisa iindlela ezinobunzima obusekwe kwiprofayili yemolekyuli kunye neendlela ezisulungekileyo zokusasazeka kwemitha. Olu tshintsho lujolise ekuphuculeni amazinga aphantsi okusinda anxulumene nesifo esibanzi.

Iprofayili yeMolekyuli kwi-SCLC

Utshintsho olubalulekileyo kwizikhokelo zika-2026 sisincomo esicacileyo seprofayili yemolekyuli ebanzi kwiiseti ezithile zeSCLC. Izigulana ezingatshayiyo, ezingatshayiyo, okanye ezo zinokungaqiniseki ngoxilongo ngoku ziphantsi kohlalutyo olubanzi lwe-genomic. Olu tshintsho luyavuma ukuba iseti yamatyala e-SCLC inokuba neenguqu ezinokubakho okanye ilinganise amanye amathumba e-neuroendocrine.

• Abantu ekujoliswe kubo: Abangatshayiyo okanye abo batshayayo ngaphantsi kweepakethi ezili-10 ngonyaka.
• Uncedo lweklinikhi: Ukuchonga iithagethi ezinokubakho kwizilingo zeklinikhi okanye ngaphandle kweleyibhile yonyango ekujoliswe kuyo.
• Ukuvavanywa kwakhona: Uvavanyo olusisinyanzelo lwemolekyuli xa luphinda lwenziwa ukuba aluzange lwenziwe ngaphambili.

Le ndlela yonyango echanekileyo izisa i-SCLC kufutshane neemodeli zonyango zomntu ezibonwa kwi-NSCLC, inika ithemba kwizigulane ezingaphenduliyo kwiirejimeni eziqhelekileyo ze-platinum-etoposide.

UkuPhuculwa koNyango lweRadiation

Imitha yethoracic ihlala iyinxalenye ebalulekileyo yonyango lwe-SCLC lwenqanaba elilinganiselweyo. Izikhokelo zamva nje zixhasa ngamandla uNyango lweRadiation-Modulated Radiation (IMRT) ngaphezulu kwemitha yemitha ehambelana nemilinganiselo emithathu (3D-CRT). Ubungqina bubonisa ukuba i-IMRT iyayinciphisa kakhulu ityhefu kwizihlunu eziphilileyo ezingqongileyo ngelixa igcina ulawulo lwe-tumor ngexesha le-chemoradiation efanayo.

Ngaphaya koko, iimpawu zotyando ziye zaqiniswa. Utyando ngoku lugcinelwe ngokungqongqo kwisigaba seklinikhi yesifo se-I-IIA esiqinisekiswe ngokuhlasela kwe-mediastinal staging. Oku kuqinisekisa ukuba kuphela izigulana ezinesifo sendawo ngokwenyani ziye zithotywe, zigweme iinkqubo ezingento yanto kwabo banento yokwenza nokubandakanyeka kobugqi.

UNyango olusakhulayo kunye neNkqubo yokuHanjiswa kweNoveli

Umbhobho we unyango lomhlaza wemiphunga yokuqala iyaqhubeka ukwanda ngeendlela ezintsha zokuqulunqa amachiza kunye neendlela zokuhambisa. Olu phuculo lujolise ekwandiseni ukulula kwesigulana, ukunciphisa ukusabela okunxulumene nokufakwa, kunye nokuphucula i-pharmacokinetics yamachiza. I-subcutaneous formulations kunye nenoveli ye-radiopharmaceuticals iphambili kolu tshintsho.

I-Subcutaneous Biologics

Ukuphucuka okubalulekileyo komgangatho wobomi kuvela ekuvunyweni kwe-subcutaneous formulations ye-monoclonal antibodies. Iiarhente ezifana ne-amivantamab, ebikade ilawulwa ngokufakwa kwi-intravenous ixesha elide, ngoku ibonelela nge-hyaluronidase-iququzelele iinketho zesitofu esingaphantsi kwesikhumba. Olu tshintsho lunciphisa kakhulu ixesha lesitulo kwizigulane kunye nokunciphisa umthwalo kumaziko okufakwa.

Ngokufanayo, i-pembrolizumab ibone uphuhliso kwezinye iindlela zokuhambisa, kubandakanywa ukwakhiwa kwenaliti ye-muscle kwiimeko ezithile. Ezi zinto zintsha zigcina ukusebenza kakuhle konyango ngelixa kulungelelaniswa inkqubo yokulawula, ukwenza unyango lwexesha elide lulawuleke ngakumbi kwizigulane ezinezifo ezingapheliyo.

Iimpumelelo zoNyango lweNyukliya

I-nuclear oncology ibone isiganeko esiyimbali ngokuvunywa kwe-technetium-99m pexipretide peptide injection. Njenge-arhente yokucinga ye-SPECT yokuqala yehlabathi ejolise kwi-integrin αvβ3, ivumela ukubonwa okuchanekileyo kwe-tumor angiogenesis. Ngelixa ngokuyintloko sisixhobo sokuxilonga, ukukwazi kwayo ukuchonga i-lymph node metastasis kwiimeko zomhlaza wemiphunga ezikrokrelayo kuphucula ukuchaneka kwezigaba.

Ukulinganisa okuchanekileyo kuchaphazela ngokuthe ngqo ukhetho lonyango, ukuqinisekisa ukuba izigulane zifumana ezona zifanelekileyo unyango lomhlaza wemiphunga yokuqala ubunzulu. Ngokwahlula phakathi kwesifo sendawo kunye nesisasazwayo esinovakalelo oluphezulu, oogqirha banokukuphepha ukunyangwa kakhulu kumanqanaba okuqala okanye banyuse unyango ngokukhawuleza kumatyala aphambili.

Uhlalutyo lokuthelekisa kwiiNdlela zoNyango

Ukukhetha unyango olulolona lufanelekileyo kufuna ukulungelelanisa ukusebenza kakuhle, ubuthi, kunye nezinto ezingqamene nesigulane. Le theyibhile ilandelayo ithelekisa iindlela eziphambili ezisetyenziswe ngo-2026 kumhlaza wemiphunga ophambili, iqaqambisa indima yabo eyahlukileyo kunyango lwendalo.

Olu thelekiso lubonisa ukuba akukho ndlela inye ifanele zonke. Intsingiselo isiya ngokucacileyo ngakwizicwangciso ezilandelelanayo okanye ezidityanisiweyo eziphakamisa amandla endlela nganye ngelixa zithomalalisa ubuthathaka bazo.

Amanyathelo asebenzayo kwizigulane kunye nabanonopheli

Ukujonga ukuxilongwa komhlaza wemiphunga kunokuba nzima. Ukuqonda ukuhamba komsebenzi wale mihla unyango lomhlaza wemiphunga yokuqala ixhobisa izigulana ukuba zibandakanyeke ngokukhutheleyo kukhathalelo lwazo. La manyathelo alandelayo achaza uhambo oluqhelekileyo ukusuka ekuxilongeni ukuya ekuqalisweni konyango kwimeko yezempilo ka-2026.

• Inyathelo 1: Inqanaba elipheleleyo: Yenza i-PET / CT kunye ne-MRI yobuchopho ukujonga ubungakanani besifo. Qinisekisa ukuba i-invasive staging mediastinal yenziwa ukuba utyando luyaqwalaselwa.
• Inyathelo 2: Iprofayile yeBiomarker: Cela uvavanyo olubanzi lwemolekyuli kuquka i-DNA kunye ne-NGS esekwe kwi-RNA. Musa ukuqala unyango lwe-immunotherapy de iziphumo zifumaneke ngaphandle kokuba zingxamisekile ngokwezonyango.
• Inyathelo lesi-3: Uphononongo lwemisebenzi emininzi: Xoxa ngamatyala kwibhodi yethumba ebandakanya oogqirha botyando, i-oncologists yezonyango, kunye ne-radiation oncologists ukwenza isicwangciso semvumelwano.
• Inyathelo lesi-4: Ukhetho loNyango: Khetha unyango olusekelwe kwimo yemolekyuli. Ukubeka phambili ii-arhente ezijoliswe kuzo kubaqhubi, zilandelwa yimidibaniso ye-chemo-immunotherapy.
• INyathelo 5: Udibaniso lweNkxaso yeNkathalelo: Faka ukhathalelo lokuthomalalisa kwangoko ukulawula iimpawu kunye neziphumo ebezingalindelekanga, ukuphucula umgangatho wobomi bubonke.

Ukuthobela le ndlela ecwangcisiweyo kuqinisekisa ukuba izigulane zifumana ukunakekelwa kwesikhokelo, ukwandisa amathuba okuba neziphumo ezihle.

Imingeni kunye nezikhokelo zexesha elizayo

Ngaphandle kwenkqubela phambili ephawulekayo, imingeni iyaqhubeka kummandla we unyango lomhlaza wemiphunga yokuqala. Ukuchasana nonyango olujoliswe kuyo kukhula ngokungaphephekiyo, kufuneke ukuba kuphuhliswe inhibitors yesizukulwana esilandelayo kunye nezicwangciso zokudibanisa. Ngaphaya koko, ukufikelela kuxilongo olukwinqanaba eliphezulu kunye namachiza anoveli kuhlala kungalingani kwimimandla eyahlukeneyo yejografi kunye nezoqoqosho.

Ukoyisa iiNdlela zokuChasa

I-Tumor heterogeneity kunye nokumelana nokuguquguquka yimiqobo emikhulu. Uphando lugxile kakhulu ekuqondeni ukuvela kweemolekyuli zamathumba phantsi koxinzelelo lonyango. Amaqhinga afana nokudosa okwethutyana, iiholide zamachiza, kunye nokudityaniswa okunengqiqo kwee-TKIs ezine-immunotherapies ziyaphononongwa ukulibazisa ukuxhathisa.

Umzekelo, kwi-HER2-umhlaza wemiphunga oguqukayo, ngelixa ii-TKI zodidi lokuqala zibonisa isithembiso, ulawulo lwesifo esisemva kokuqhubela phambili luhlala luyindawo yophando olusebenzayo. I-antibody-drug conjugates iyaqhubeka nokudlala indima ebalulekileyo apha, inika indlela yokusebenza eyahlukileyo kwi-kinase inhibition.

Ukufikeleleka kunye nokuLingana

Ixabiso eliphezulu lee-arhente zenoveli kunye novavanyo oluntsonkothileyo lokuxilonga lubeka umqobo kufikelelo jikelele. Amanyathelo okunciphisa iindleko ngokusebenzisa ii-biosimilars kunye namangenelo aqhelekileyo abalulekile. Ukongeza, i-telemedicine kunye nezixhobo zempilo yedijithali ziyaxhatshazwa ukuzisa ukubonisana kweengcali kwiindawo ezikude, ukuvala umsantsa kumgangatho wokhathalelo.

Iinzame zokuphelisa iyantlukwano zikwabandakanya iinkqubo zovavanyo loluntu kunye namaphulo okufundisa ukufumanisa umhlaza wemiphunga kwangethuba, amanqanaba anyangekayo. Ukufunyaniswa kwangethuba kusesona sicwangciso sisebenzayo sokunciphisa amazinga okubhubha kwihlabathi jikelele.

Imibuzo Ebuzwa Rhoqo malunga noNyango loMhlaza weMiphunga

Izigulana zihlala zinemibuzo ethile malunga nama-nuances oxilongo lwabo kunye nokhetho lonyango. Ukujongana nale mibuzo ixhaphakileyo kunceda ukucacisa imeko yezonyango enzima ka-2026.

Ngaba utyando luselukhetho lwenqanaba lesithathu lomhlaza wemiphunga?

Utyando kwisigaba sesi-III sesifo sikhetha kakhulu kwaye ngokuqhelekileyo sigcinelwe amacandelwana athile (umzekelo, i-T3N1 okanye i-T4N0 ekhethiweyo) emva konyango oluyimpumelelo lwe-neoadjuvant. Uninzi lwezigulane zenqanaba le-III zilawulwa nge-chemoradiation ecacileyo elandelwa yi-consolidation immunotherapy. Isiteji esihlaselayo sinyanzelekile ukuba sithintele isifo esinganyangekiyo se-nodal.

Kuthatha ixesha elingakanani uvavanyo lwebiomarker?

Amaxesha okujika ayohluka ngokwelabhoratri kodwa ngokubanzi asusela kwiintsuku ezisi-7 ukuya kwezili-14 kwiiphaneli ze-NGS ezibanzi. Uvavanyo olukhawulezayo olusekwe kwiplasma lunokubonelela ngeziphumo zokuqala kwangoko. Oogqirha bayacetyiswa ukuba balinde iziphumo ezipheleleyo ngaphambi kokuba bazibophelele kwisicwangciso sonyango lwexesha elide, ngaphandle kweemeko ezingxamisekileyo.

Zeziphi iziphumo ebezingalindelekanga zonyango olujoliswe kuzo olutsha?

Ngelixa ngokuqhelekileyo inyamezeleke ngakumbi kune-chemotherapy, i-TKIs inokubangela iziganeko ezithile ezimbi ezifana ne-rash, isifo sohudo, okanye isifo se-lung interstitial. Ukubeka iliso rhoqo kunye nolawulo olusebenzayo lubalulekile. Iprofayili yokhuseleko lwama-agent amatsha afana ne-zonugritinib ibonisa iziganeko eziphantsi ze-toxicity enzima, kunye neziganeko ezininzi ezilawulekayo.

Isiphelo: Ixesha le-Oncology echanekileyo

Unyaka ka-2026 uphawula ixesha eliqinisekileyo unyango lomhlaza wemiphunga yokuqala, ephawulwa ngobuntu obungazange bubonwe ngaphambili kunye nokuchaneka. Ukususela ekwamkelweni jikelele kwe-AJCC yoHlelo lwesi-9 ukuya ekudityanisweni kwee-arhente ezijoliswe kuzo ezinoveli kutshintsho olunqabileyo olufana ne-HER2, intsimi ikhule kakhulu. Ugxininiso kuvavanyo olubanzi lwe-biomarker luqinisekisa ukuba isigulana ngasinye sifumana unyango olulungiselelwe i-tumor biology yaso eyodwa.

Njengoko uphando luqhubeka nokutyhila ubunzima bomhlaza wemiphunga, umsantsa phakathi kokuxilongwa kunye nonyango olusebenzayo uyancipha. Ukwenziwa kwezinto ezintsha ekuhanjisweni kweziyobisi, ubuchule bokusasazeka kwemitha, kunye nokucinga koxilongo kuphucula ngakumbi isixhobo soogqirha. Ngelixa imiceli mngeni malunga nokuxhathisa kunye nokufikeleleka kusekho, indlela elandelwayo icacile: ikamva apho umhlaza wemiphunga uye ulawulwa kakhulu njengemeko engapheliyo, elawulekayo kunokuba uxilongo olubulalayo.

Izigulane kunye nababoneleli ngokufanayo kufuneka bahlale benolwazi malunga nolu kuqhubela phambili ngokukhawuleza. Ukuthotyelwa kwezikhokelo ezihlaziyiweyo, ukuthatha inxaxheba kwizilingo zeklinikhi, kunye nokuzibophelela ekunakekelweni kweenkalo ezininzi ziyintsika zempumelelo kulo mhlaba uguqukayo. Uhambo olusingise ekupheliseni umhlaza wemiphunga njengoyena nobangela uphambili wokufa luyaqhubeka, luqhutywa yinzululwazi, uvelwano, kunye nokusungula izinto ezintsha ezingayekeleliyo.